Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity

doi:10.1016/j.jphs.2017.10.007

CORC > 昆明植物研究所 > 中国科学院昆明植物研究所 > 植物化学与西部植物资源持续利用国家重点实验室

	Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity
	Niu, Yanfen 1,3,7; Li, Hongjian 2,4; Gao, Lihui 3; Lin, Hua 3; Kung, Hsiangfu 3,5; Lin, Marie Chia-mi 3,6; Leung, Kwong-Sak 2,4; Wong, Man-Hon 4; Xiong, Wenyong1 ; Li, Ling 3
刊名	JOURNAL OF PHARMACOLOGICAL SCIENCES
	2017-11-01
卷号	135 期号:3 页码:114-120
关键词	Olsalazine Sodium Hyperuricemia Xanthine Oxidase Uric Acid
ISSN号	1347-8613
DOI	10.1016/j.jphs.2017.10.007
英文摘要	Hyperuricemia, a long-term purine metabolic disorder, is a well-known risk factor for gout, hypertension and diabetes. In maintaining normal whole-body purine levels, xanthine oxidase (XOD) is a key enzyme in the purine metabolic pathway, as it catalyzes the oxidation of hypoxanthine to xanthine and finally to uric acid. Here we used the protein-ligand docking software idock to virtually screen potential XOD inhibitors from 3167 approved small compounds/drugs. The inhibitory activities of the ten compounds with the highest scores were tested on XOD in vitro. Interestingly, all the ten compounds inhibited the activity of XOD at certain degrees. Particularly, the anti-ulcerative-colitis drug olsalazine sodium demonstrated a great inhibitory activity for XOD (IC50 = 3.4 mg/L). Enzymatic kinetic studies revealed that the drug was a hybrid-type inhibitor of xanthine oxidase. Furthermore, the drug strikingly decreased serum urate levels, serum/hepatic activities of XOD at a dose-dependent manner in vivo. Thus, we demonstrated a successful hunting process of compounds/drugs for hyperuricemia through virtual screening, supporting a potential usage of olsalazine sodium in the treatment of hyperuricemia. (c) 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
语种	英语
WOS记录号	WOS:000418237700003
内容类型	期刊论文
源URL	[http://ir.kib.ac.cn/handle/151853/60477]
专题	昆明植物研究所_植物化学与西部植物资源持续利用国家重点实验室
作者单位	1.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China 2.Chinese Univ Hong Kong, Inst Future Cities, Hong Kong, Hong Kong, Peoples R China 3.Kunming Med Univ, Biomed Engn Res Ctr, 1168 Western Chunrong Rd,Yuhua St, Kunming 650500, Yunnan, Peoples R China 4.Chinese Univ Hong Kong, Dept Comp Sci & Engn, Hong Kong, Hong Kong, Peoples R China 5.Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China 6.Shenzhen Univ, Sch Med, Shenzhen Key Lab Translat Med Tumor, Shenzhen, Peoples R China 7.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
推荐引用方式 GB/T 7714	Niu, Yanfen,Li, Hongjian,Gao, Lihui,et al. Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity[J]. JOURNAL OF PHARMACOLOGICAL SCIENCES,2017,135(3):114-120.
APA	Niu, Yanfen.,Li, Hongjian.,Gao, Lihui.,Lin, Hua.,Kung, Hsiangfu.,...&Li, Ling.(2017).Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity.JOURNAL OF PHARMACOLOGICAL SCIENCES,135(3),114-120.
MLA	Niu, Yanfen,et al."Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity".JOURNAL OF PHARMACOLOGICAL SCIENCES 135.3(2017):114-120.